What Granules Pharmaceuticals does

Granules Pharmaceuticals Inc. (GPI) is a 100% US-based pharmaceutical subsidiary of Granules India Limited, headquartered at 3701 Concorde Parkway, Chantilly, Virginia, where it operates a US FDA- and DEA-approved manufacturing facility spanning over 100,000 square feet. As of the fiscal year ended March 31, 2025, GPI employs 340+ US staff, has filed 34 Abbreviated New Drug Applications (ANDAs) with 31 approved and 3 under review, and has commercialized 43 prescription pharmaceutical products spanning therapeutic categories including central nervous system (Schedule II stimulants for ADHD such as mixed amphetamine salts, methylphenidate ER, dexmethylphenidate ER, and lisdexamfetamine; antidepressants including sertraline, fluoxetine, bupropion, venlafaxine, trazodone; anticonvulsants), pain management (Schedule II opioid combinations hydrocodone/acetaminophen and oxycodone/acetaminophen, plus NSAIDs naproxen and ibuprofen), cardiovascular (potassium chloride ER, metoprolol succinate ER, losartan), metabolic disorders (metformin IR/ER), gastrointestinal (esomeprazole DR, pantoprazole DR), and other categories. An additional 20 products are commercialized under private label by its wholly owned LLC subsidiary Granules Consumer Health (GCH).

GPI's core manufacturing capabilities focus on complex, low-volume oral solid dosage forms—immediate-release tablets and capsules, multi-particulate pellets with modified-release properties, delayed-release and extended-release formulations, orally disintegrating modified-release dosage forms, chewable modified-release tablets, a patentable Microspheres technology platform, powders for oral solution reconstitution, and modified-release suspensions. These capabilities are produced in compliance with Trade Agreements Act (TAA) standards. The company's technical differentiation rests on vertically integrated manufacturing spanning API to finished dosage forms, leveraging Granules India's global manufacturing scale to support US-market production.

The go-to-market model is dual-channel: GPI commercializes its own ANDA-approved prescription generics through the US pharmacy distribution network and direct sales to healthcare providers, while GCH serves as the front-end division for private label OTC generics supplied to retail store brand partners. The company was previously known as Granules USA and traces its US commercial operations to its 2018 first-product launch. Leadership comprises President Vijay Ramanavarapu, CFO Kamal Mandan (joined September 2018), Chief Commercial Officers David Rekenthaler and Jason Hanks, SVP Sales & Marketing Rajesh Narra, EVP Strategy & Business Development Cormac Long, and President of GCH Nivaran Kapur. No revenue is publicly disclosed; the entity is privately held as a wholly owned subsidiary of the publicly listed parent Granules India Limited.

Name

Granules Pharmaceuticals

Legal name

Granules Pharmaceuticals Inc.

Website

https://granulespharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Short description

Granules Pharmaceuticals Inc. (GPI) is a US-based, FDA- and DEA-approved subsidiary of Granules India that manufactures and commercializes complex generic prescription drugs and Schedule II controlled substances, while its GCH division supplies private label OTC products to US retail store brand partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Generic pharmaceuticals
• Oral solid dosage forms
• ANDA approved drugs
• Private label OTC
• Controlled substance manufacturing

Headquarters

HQ city

Chantilly

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

1. Prescription Generic Pharmaceuticals: Commercialization of ANDA-approved generic prescription pharmaceuticals including controlled substances, cardiovascular drugs, neurological medications, and pain management products through pharmacy channels.
2. Private Label OTC Products: Granules Consumer Health (GCH) provides private label OTC generic products to store brand partners in the US retail market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Granules Pharmaceuticals Inc. (GPI) is a US FDA- and DEA-approved pharmaceutical manufacturer specializing in complex, low-volume oral solid dosage forms—tablets, capsules, powders, and oral solutions—developed in compliance with TAA standards. GPI commercializes ANDA-approved generic prescription pharmaceuticals through US pharmacy distribution, while its wholly owned subsidiary Granules Consumer Health (GCH) supplies private-label OTC generic products to retail store brand partners.

Product overview

Granules Pharmaceuticals Inc. (GPI) is a 100% US-based pharmaceutical subsidiary of Granules India, offering a comprehensive portfolio of generic prescription and OTC drugs. The company's core offering spans complex, low-volume oral solid dosage forms including immediate-release tablets, extended-release tablets, capsules, oral solutions, and powders for reconstitution. GPI operates through two main divisions: the prescription drug business (GPI) and the private label OTC segment through its wholly owned subsidiary Granules Consumer Health (GCH). The product portfolio includes approximately 60+ commercialized products across therapeutic areas such as CNS/neurology (ADHD medications like amphetamine products, methylphenidate, gabapentin; antidepressants like sertraline, fluoxetine, bupropion, venlafaxine, trazodone), pain management (opioids including hydrocodone and oxycodone combinations, naproxen, ibuprofen, butalbital products), cardiovascular (potassium chloride supplements, metoprolol, losartan), metabolic disorders (metformin products), gastrointestinal (esomeprazole, pantoprazole), and epilepsy treatments (levetiracetam, lamotrigine, zonisamide). Manufacturing capabilities include immediate-release tablets and capsules, multi-particulate pellets with modified-release technology, microspheres technology platform, delayed and extended-release formulations, orally disintegrating and chewable modified-release forms, and modified-release suspensions. As of March 31, 2025, GPI has filed 34 ANDAs with 31 approved and 3 under review, and has commercialized 43 products.

Differentiator

Problem solved

Functional benefit

Brands

• Granules Consumer Health (GCH): Wholly owned LLC serving as the front-end division for private label OTC products in the US, offering OTC generics and products to store brand partners.

Products and services

• Amphetamine Sulfate Tablets, USP

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Granules India LimitedcoreStrategic or Co-development PartnerGranules India Limited is the parent company and global manufacturing backbone for Granules Pharmaceuticals Inc. GPI is a 100% US-based subsidiary that leverages Granules India's global manufacturing strength. Granules India filed 17 of the 43 products commercialized by GPI, demonstrating integrated product development and supply chain coordination.
• Granules Consumer Health (GCH)coreStrategic or Co-development PartnerWholly owned LLC subsidiary of Granules Pharmaceuticals that serves as the front-end division for private label OTC products in the US. GCH commercialized 20 additional products under private label for store brand partners.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Perrigo Company: US leader in private-label OTC and store-brand consumer health products, directly comparable to GPI's Granules Consumer Health (GCH) division. Comparable channel and customer set with major retail store-brand partners.
• Glenmark Pharmaceuticals: India-based generic pharmaceutical company with US sales of oral solid and specialty generics including dermatology and respiratory. Comparable in being an India-headquartered parent commercializing ANDA-approved generics through a US arm.
• Amneal Pharmaceuticals: US-focused generic and specialty pharma manufacturer with a strong controlled-substance franchise (ADHD, pain) and complex modified-release capabilities. Closest US-headquartered analog to GPI's specialty generic positioning.
• Zydus Pharmaceuticals (USA): US arm of India's Zydus Cadila, manufacturing and commercializing oral solid generic prescription drugs in the US from an FDA-approved facility. Highly comparable mid-tier Indian-affiliated US generics player with complex formulations.
• Aurobindo Pharma (USA): US subsidiary of Indian generic major Aurobindo Pharma with a similarly broad portfolio of oral solid generic prescription drugs plus an Aurohealth private-label OTC arm. Directly comparable business model, scale, and India-to-US integration approach as GPI/GCH.
• Lupin Pharmaceuticals: Indian-headquartered generic manufacturer with substantial US operations commercializing oral solid generics including controlled substances and complex formulations. Direct competitor for GPI's portfolio breadth and parent-subsidiary integration model.
• Apotex: Canadian-based generic manufacturer with significant US presence commercializing oral solid generics and OTC products. Comparable mid-tier generics competitor with similar FDA-approved manufacturing footprint.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep US oral-solid generic portfolio including controlled substances. Overlaps with GPI across most therapeutic categories but operates at much greater scale with broader portfolio.
• Viatris: Global generics and specialty pharma company formed from Mylan-Upjohn combination, offering oral-solid generics across GPI's therapeutic areas including CNS, CV, and pain. Broad incumbent with overlapping but much more extensive product portfolio.
• Sandoz (Novartis): Global generic and biosimilar leader with substantial US oral-solid generic business across all GPI therapeutic categories. Broad incumbent with overlapping capabilities but significantly larger scale and breadth than GPI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/granules-pharmaceuticals-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Granules Pharmaceuticals